Ars Pharmaceuticals, Inc. company information, Employees & Contact Information

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) Yahoo Finance

ARS Pharmaceuticals Receives Favorable Decision from GlobeNewswire

EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 Stock Titan

ARS Pharma drops 9% as Lupin files application for generic neffy Seeking Alpha

ARS Pharmaceuticals and Alfresa Holdings Receive Japanese Approval for neffy® Epinephrine Nasal Spray to Treat Anaphylaxis | SPRY Stock News Quiver Quantitative

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results GlobeNewswire

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians Yahoo Finance

$250M Financing Deal: ARS Pharma's Needle-Free Allergy Treatment neffy Targets $2B Market Opportunity Stock Titan

ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) Seeking Alpha

ARS Pharmaceuticals Secures Up to $250 Million Loan GlobeNewswire

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) Yahoo Finance

ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results Stock Titan

89% Success Rate: Revolutionary Nasal Spray neffy Matches Standard Injection for Life-Threatening Allergies Stock Titan

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire

Real-World Evidence Supports Clinical Effectiveness of GlobeNewswire

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates GlobeNewswire

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray) Yahoo Finance

First-Ever Needle-Free Anaphylaxis Treatment: ARS Pharma's neffy Approved in Japan for 900K Patients Stock Titan

ARS Pharma Q1 Earnings: First Needle-Free Epinephrine Spray Hits $7.8M Revenue, 57% Insurance Coverage Stock Titan

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg GlobeNewswire

Anaphylaxis Treatment Developer ARS Pharmaceuticals Announces Key September Investor Conference Schedule Stock Titan

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to Yahoo Finance

ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season Nasdaq

Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment Stock Titan

Gilead's Yeztugo, Eisai's Leqembi Iqlik, Vertex's Journavx among 2025's best inventions: Time Fierce Pharma

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and GlobeNewswire

FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients Pharmaceutical Executive

ARS Pharmaceuticals' Neffy Nasal Spray Hits $7.1M in Sales Since Launch, Targets 80% Insurance Coverage Stock Titan

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal GlobeNewswire

ARS Pharmaceuticals Announces Planned Launch of GlobeNewswire

Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients Stock Titan

With US launch progressing, ARS inks another licensing deal for epinephrine spray Neffy worth up to $465M Fierce Pharma

ALK-Abelló pays $145M to add epinephrine nasal spray to portfolio FirstWord Pharma

ARS Pharmaceuticals Announces Exclusive Agreement with GlobeNewswire

In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says Fierce Pharma

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter Yahoo Finance

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference Yahoo Finance

ARS Pharmaceuticals Announces U.S. Availability of neffy® GlobeNewswire

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results Investing News Network

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis Yahoo Finance

ARS Pharmaceuticals hit with surprise FDA rejection for epinephrine nasal spray Neffy, vows to appeal Fierce Pharma

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis Yahoo Finance

FDA Issues Complete Response Letter for neffy® (epinephrine GlobeNewswire

As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray Fierce Pharma

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis Santé log

NEURELIS CONGRATULATES INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, FOR FDA ACCEPTANCE OF INTRANASAL EPINEPHRINE NDA PR Newswire

SPRY Stock Price and Chart — NASDAQ:SPRY TradingView

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics GlobeNewswire

Meet Neffy, the friendly epinephrine nasal spray from ARS Pharma awaiting FDA approval Fierce Pharma

ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray) PR Newswire

Positive Data for ARS Pharma San Diego Business Journal

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy™ (ARS-1; epinephrine nasal spray) PR Newswire

US FDA approves nasal spray alternative to EpiPen for allergic reactions The Straits Times